Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Mesothelioma, Malignant 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neoplasms 1

Interventions

Cisplatin 6Pemetrexed 5cediranib 3Chemotherapy, Adjuvant 3Radiotherapy 2Neoadjuvant Therapy 2Gemcitabine 2vatalanib 1rilotumumab 1pembrolizumab 1belinostat 1Watchful Waiting 1Vinorelbine 1Talc 1Sorafenib 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pharmacogenomic Testing 1Methotrexate 1Immunoenzyme Techniques 1Gefitinib 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Dasatinib 1Capecitabine 1Bevacizumab 1ARQ 197 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumor, Pleural × ARQ 197 × Thoracic × Clear all
NCT01861301 2016-10-24

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Terminated
18 enrolled 7 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡